CTP-656 is a novel deuterium-modified version of ivacaftor. Ivacaftor is commercially available under the name Kalydeco®. The clinical trial results continue to support the development of CTP-656 as
BiCNU is primarily used for chemotherapy in the treatment of several types of brain cancer, multiple myeloma and lymphoma (Hodgkin’s and non-Hodgkin). BiCNU is also sometimes used for
Under the agreement, BioQ Pharma is responsible for developing and supplying the unit-dose infusion pharmaceutical, and Sandoz is responsible for obtaining regulatory approval, marketing and commercializing the product.
The enrollment in the US has reached 36 patients, exceeding the minimum of 30 patients proposed by the United States Food and Drug Administration (FDA). The last patient
ALKS 7119 is being developed for the treatment of agitation in patients with Alzheimer’s disease and other central nervous system (CNS) indications. Based on initial blinded data from
The facility will supply RNAi therapeutics for Alnylam’s clinical and commercial needs. The location, selected in close collaboration with Commonwealth and local officials, demonstrates Alnylam’s ongoing commitment to
Therabron Therapeutics’ lead biopharmaceutical product candidate is a proprietary preparation of recombinant human CC10 protein which has potential clinical applications, based on its potent anti-inflammatory properties, in a
The phase IIb trial is a global multicentric study, randomized versus placebo, started in October last year in Lupus. It intends to assess the biological and clinical efficacy
The US Food and Drug Administration (FDA) has cleared Cumberland’s investigational new drug application (IND) for Phase II clinical program for Vasculan in patients with systemic sclerosis. "Cumberland
X-Chem met this milestone under a partnership established with Alexion in December 2014. Under the terms of the agreement, Alexion obtains exclusive worldwide rights to develop and commercialize
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.